Allspring Global Investments Holdings LLC Has $415,000 Stake in 10x Genomics, Inc. (NASDAQ:TXG)

Allspring Global Investments Holdings LLC decreased its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 25.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,238 shares of the company’s stock after selling 9,725 shares during the period. Allspring Global Investments Holdings LLC’s holdings in 10x Genomics were worth $415,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Capital Performance Advisors LLP acquired a new position in shares of 10x Genomics in the 3rd quarter valued at about $35,000. Blue Trust Inc. increased its holdings in shares of 10x Genomics by 136.5% in the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after purchasing an additional 1,025 shares during the period. Sound Income Strategies LLC increased its holdings in shares of 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after purchasing an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of 10x Genomics in the 4th quarter valued at approximately $52,000. Finally, Venturi Wealth Management LLC grew its stake in shares of 10x Genomics by 1,108.9% in the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock valued at $55,000 after buying an additional 2,240 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

Analyst Upgrades and Downgrades

TXG has been the subject of several recent research reports. The Goldman Sachs Group lowered their price target on 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research note on Wednesday, October 30th. Stifel Nicolaus lowered their price target on 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Citigroup lowered their price target on 10x Genomics from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a research note on Wednesday, February 19th. Finally, JPMorgan Chase & Co. lowered their price target on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, 10x Genomics presently has an average rating of “Hold” and a consensus target price of $20.57.

10x Genomics Stock Up 3.6 %

Shares of TXG stock opened at $11.29 on Tuesday. 10x Genomics, Inc. has a 12 month low of $10.63 and a 12 month high of $48.42. The firm has a market cap of $1.38 billion, a PE ratio of -7.43 and a beta of 1.85. The stock has a 50 day moving average of $14.23 and a 200-day moving average of $17.02.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. As a group, equities analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.